BioWorld1d
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the ...
Kura Oncology Cancer Study Hits Primary Goal, Lays Out Plans For Phase 3 Studies
Kura Oncology and Kyowa Kirin reported positive Phase 2 results for ziftomenib in AML and plan Phase 3 trials, with an NDA ...
Kura Oncology stock target raised to $40 by H.C. Wainwright
H.C. Wainwright maintained a Buy rating on Kura Oncology (NASDAQ:KURA) and raised the price target to $40.00 from the previous $37.00. Trading at $9.05, the stock has seen a strong 12.7% gain over the ...
BTIG cuts Kura Oncology stock rating to Neutral
BTIG analyst Justin Zelin downgraded Kura Oncology stock (NASDAQ:KURA) from Buy to Neutral. Zelin cited concerns over the recent KOMET-001 study results for the company's drug, ziftomenib. The ...
Kura Oncology price target raised to $36 from $34 at Wedbush
Wedbush analyst Robert Driscoll raised the firm’s price target on Kura Oncology (KURA) to $36 from $34 and keeps an Outperform rating on the ...
BioSpace1d
Kura Eyes FDA Filing After Pivotal AML Win, but Investors Aren’t Impressed
Kuro Oncology and partner Kyowa Kirin are on track for an NDA submission for ziftomenib in the second quarter of this year.
Kura, Kyowa Kirin announce KOMET-001 results, FDA feedback for trial designs
Kura Oncology (KURA) and Kyowa Kirin announced topline results from KOMET-001, the Phase 2 registration-directed trial of ziftomenib, a highly ...